{"filing":{"accession_number":"0001326190-26-000049","cik":"0001326190","ticker":"ALT","company_name":"Altimmune, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"alt-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812x8k.htm"},"events":[{"id":27042,"run_id":24612,"accession_number":"0001326190-26-000049","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Altimmune issued a press release on August 12, 2026 announcing financial results for Q2 2026 ended June 30, 2026, including consolidated balance sheets and statements of operations. The disclosure includes quarterly financial metrics (R\u0026D expenses of $18.7M, G\u0026A expenses of $7.6M, net loss of $22.8M), cash position of $519M, and material clinical milestones (PERFORMA Phase 3 initiation, RECLAIM Phase 2 positive data, RESTORE Phase 2 enrollment completion). This is a standard quarterly earnings release with financial statements and business updates furnished as Exhibit 99.1.","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28401,"accession_number":"0001326190-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Altimmune issued a press release on August 12, 2026 announcing financial results for Q2 2026 ended June 30, 2026, including consolidated balance sheets and statements of operations. The disclosure includes quarterly financial metrics (R\u0026D expenses of $18.7M, G\u0026A expenses of $7.6M, net loss of $22.8M), cash position of $519M, and material clinical milestones (PERFORMA Phase 3 initiation, RECLAIM Phase 2 positive data, RESTORE Phase 2 enrollment completion). This is a standard quarterly earnings release with financial statements and business updates furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:34:38.180042+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28401,"accession_number":"0001326190-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Altimmune issued a press release on August 12, 2026 announcing financial results for Q2 2026 ended June 30, 2026, including consolidated balance sheets and statements of operations. The disclosure includes quarterly financial metrics (R\u0026D expenses of $18.7M, G\u0026A expenses of $7.6M, net loss of $22.8M), cash position of $519M, and material clinical milestones (PERFORMA Phase 3 initiation, RECLAIM Phase 2 positive data, RESTORE Phase 2 enrollment completion). This is a standard quarterly earnings release with financial statements and business updates furnished as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:34:38.180042+00:00","company_name":"Altimmune, Inc.","ticker":"ALT","filing_date":"2026-08-12"}]}